<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01350804</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457F2309</org_study_id>
    <secondary_id>2011-000102-21</secondary_id>
    <nct_id>NCT01350804</nct_id>
    <nct_alias>NCT01640938</nct_alias>
  </id_info>
  <brief_title>Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)</brief_title>
  <acronym>NURTURE 1</acronym>
  <official_title>A Randomized, Double-blind, Placebo- and Active-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 1 Year in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents (CAIN457F2309) and A Four Year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Rheumatoid Arthritis (CAIN457F2309E1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The core and extension studies assessed the safety and efficacy of secukinumab when added to
      a background therapy in patients with active rheumatoid arthritis who are intolerant to or
      have had an inadequate response to anti-TNF-α agents. Patients received either secukinumab,
      placebo or abatacept (active comparator). The core study was completed. However, the
      extension study was prematurely terminated after the primary endpoint analysis of the core
      study at week 24 had demonstrated numerically higher efficacy for the active comparator
      abatacept compared to secukinumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).</measure>
    <time_frame>week 24</time_frame>
    <description>ACR20 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20 response results at week 24 used non-responder imputation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, &quot;are you able to...&quot; perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR50</measure>
    <time_frame>week 24</time_frame>
    <description>ACR50 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 50% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR50 response results at week 24 used non-responder imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation</measure>
    <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data</measure>
    <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52</time_frame>
    <description>ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient's assessment of RA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20, ACR50 and ACR70 response results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)</measure>
    <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, &quot;are you able to...&quot; perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI - Observed Data</measure>
    <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52</time_frame>
    <description>The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, &quot;are you able to...&quot; perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement. The HAQ-DI results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM</measure>
    <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data</measure>
    <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52</time_frame>
    <description>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement. The DAS28-CRP results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in hsCRP - Observed Data</measure>
    <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52</time_frame>
    <description>Blood samples were obtained to identify the presence of inflammation, to determine its severity and to monitor response to treatment. A negative change from baseline indicates improvement. The hsCRP results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data</measure>
    <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52</time_frame>
    <description>Blood samples were obtained to monitor disease activity and response to treatment. A negative change from baseline indicates improvement. The ESR results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">551</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>AIN457 10mg/kg - 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 10mg/kg - 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <description>AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.</description>
    <arm_group_label>AIN457 10mg/kg - 75 mg</arm_group_label>
    <arm_group_label>AIN457 10mg/kg - 150 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Abatacept</arm_group_label>
    <other_name>Secukinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.</description>
    <arm_group_label>Abatacept</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating female patients

          -  Presence of RA classified by ACR 2010 revised criteria for at least 3 months before
             screening

          -  At Baseline: Disease activity criteria defined by &gt;= 6 tender joints out of 68 and &gt;=
             6 swollen joints out of 66

        WITH at least 1 of the following at screening:

          -  Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibodies positive OR

          -  Rheumatoid Factor positive

        AND WITH at least 1 of the following at screening:

          -  High sensitivity C-Reactive Protein (hsCRP) &gt;= 10 mg/L OR

          -  Erythrocyte Sedimentation Rate (ESR) &gt;= 28 millimeter (mm)/1st hour

          -  Patients must have been taking at least one anti-TNF-α agent given at an approved dose
             for at least 3 months before randomization and have experienced an inadequate response
             to treatment or have been intolerant to at least one administration of an anti-TNF-α
             agent

          -  Patients must be taking MTX or any other DMARD (but not more than 1 DMARD) for at
             least 3 months before randomization and have to be on a stable dose at least 4 weeks
             before randomization (7.5 to 25 mg/week for MTX or other DMARD at maximum tolerated
             dose)

        Exclusion Criteria:

          -  Chest x-ray with evidence of ongoing infectious or malignant process, obtained within
             3 months prior to screening and evaluated by a qualified physician

          -  RA patients functional status class IV according to the ACR 1991 revised criteria

          -  Patients who have ever received biologic immunomodulating agents except for those
             targeting TNFα

          -  Previous treatment with any cell-depleting therapies

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207-5710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vestavia</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freemont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morton Grove</city>
        <state>Illinois</state>
        <zip>60053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eagan</city>
        <state>Minnesota</state>
        <zip>55121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>66160-7330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond Heights</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22271-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04023-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Russe</city>
        <zip>7000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevlievo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruntal</city>
        <zip>792 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <zip>772 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34195</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52064</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cottbus</city>
        <zip>03042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91056</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gommern</city>
        <zip>39245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zerbst</city>
        <zip>39261</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valeggio Sul Mincio</city>
        <state>(vr)</state>
        <zip>37067</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California</state>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Culiacan</city>
        <state>Sinaloa</state>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iasi</city>
        <zip>700195</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Korolev</city>
        <zip>141060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tula</city>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Banska Bystrica</city>
        <state>Slovak Republic</state>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Piestany</city>
        <zip>92112</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <results_first_submitted>January 26, 2016</results_first_submitted>
  <results_first_submitted_qc>May 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 23, 2016</results_first_posted>
  <last_update_submitted>May 4, 2016</last_update_submitted>
  <last_update_submitted_qc>May 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>ACR</keyword>
  <keyword>inflammatory joints</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>At baseline, participants were randomized to 1 of 4 treatment groups. Placebo non-responders at week16 were re-randomized to receive AIN457 75mg or AIN457 150mg. Placebo responders at Week16 were re-randomized to receive AIN457 75mg or AIN457 150mg at Week24. Fifteen participants from the placebo group discontinued prior to re-randomization.</recruitment_details>
      <pre_assignment_details>Abatacept responders at Week16 continued on abatacept and non-responders at Week 16 were re-randomized to begin either AIN457 75mg or AIN457 150mg at Week 24. Of the 551 core study participants, 254 participants entered the extension study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AIN457 10mg/kg - 75 mg</title>
          <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>AIN457 10mg/kg - 150 mg</title>
          <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
        </group>
        <group group_id="P4">
          <title>Abatacept</title>
          <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="138"/>
                <participants group_id="P4" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="137">1 participant actually received placebo; participant was reassigned to placebo for safety analysis.</participants>
                <participants group_id="P2" count="136">1 participant did not receive treatment; therefore participant was not counted in safety analysis.</participants>
                <participants group_id="P3" count="139">1 participant actually received placebo; participant was reassigned to placebo for safety analysis.</participants>
                <participants group_id="P4" count="137">1 participant did not receive treatment; therefore participant was not counted in safety analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Tratment Switch to AIN457 at Week 16</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="78">15 participantsdiscontinued prior to the treatment switch</participants>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment Switch to AIN457 at Week 24</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="138"/>
                <participants group_id="P4" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study, Weeks 52 - 260</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="72">During the extension, these participants received AIN457.</participants>
                <participants group_id="P4" count="23">During the extension, these participants received AIN457.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="64"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AIN457 10mg/kg - 75 mg</title>
          <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>AIN457 10mg/kg - 150 mg</title>
          <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
        </group>
        <group group_id="B4">
          <title>Abatacept</title>
          <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="138"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="138"/>
            <count group_id="B4" value="138"/>
            <count group_id="B5" value="551"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="107"/>
                    <measurement group_id="B5" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).</title>
        <description>ACR20 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient’s assessment of RA pain, patient’s global assessment of disease activity, physician’s global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20 response results at week 24 used non-responder imputation.</description>
        <time_frame>week 24</time_frame>
        <population>Full analysis set: the full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20).</title>
          <description>ACR20 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient’s assessment of RA pain, patient’s global assessment of disease activity, physician’s global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20 response results at week 24 used non-responder imputation.</description>
          <population>Full analysis set: the full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="30.7"/>
                    <measurement group_id="O3" value="18.1"/>
                    <measurement group_id="O4" value="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0458</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0152</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)</title>
        <description>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient’s Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and week 24 were analyzed. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP)</title>
          <description>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient’s Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and week 24 were analyzed. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="0.115"/>
                    <measurement group_id="O2" value="-1.47" spread="0.119"/>
                    <measurement group_id="O3" value="-1.02" spread="0.163"/>
                    <measurement group_id="O4" value="-2.07" spread="0.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)</title>
        <description>The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, &quot;are you able to...&quot; perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.</description>
        <time_frame>baseline, week 24</time_frame>
        <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and week 24 were analyzed. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Stanford Health Assessment Questionnaire Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, &quot;are you able to...&quot; perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and week 24 were analyzed. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.049"/>
                    <measurement group_id="O2" value="-0.39" spread="0.051"/>
                    <measurement group_id="O3" value="-0.26" spread="0.065"/>
                    <measurement group_id="O4" value="-0.61" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR50</title>
        <description>ACR50 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 50% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient’s assessment of RA pain, patient’s global assessment of disease activity, physician’s global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR50 response results at week 24 used non-responder imputation.</description>
        <time_frame>week 24</time_frame>
        <population>Full analysis set: the full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR50</title>
          <description>ACR50 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 50% improvement in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient’s assessment of RA pain, patient’s global assessment of disease activity, physician’s global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR50 response results at week 24 used non-responder imputation.</description>
          <population>Full analysis set: the full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="16.8"/>
                    <measurement group_id="O3" value="9.4"/>
                    <measurement group_id="O4" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation</title>
        <description>ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient’s assessment of RA pain, patient’s global assessment of disease activity, physician’s global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR).</description>
        <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <population>Participants from the full analysis set were considered for the analysis. Participants with missing data were considered non-responders at the respective time point. Placebo and Abatacept participants were considered non-responders from the time of treatment switch.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Using Non-responder Imputation</title>
          <description>ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient’s assessment of RA pain, patient’s global assessment of disease activity, physician’s global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR).</description>
          <population>Participants from the full analysis set were considered for the analysis. Participants with missing data were considered non-responders at the respective time point. Placebo and Abatacept participants were considered non-responders from the time of treatment switch.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR20, week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="7.2"/>
                    <measurement group_id="O4" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20, week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="21.2"/>
                    <measurement group_id="O3" value="12.3"/>
                    <measurement group_id="O4" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20, week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="27.0"/>
                    <measurement group_id="O3" value="21.7"/>
                    <measurement group_id="O4" value="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20, week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="41.6"/>
                    <measurement group_id="O3" value="21.0"/>
                    <measurement group_id="O4" value="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20, week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="33.6"/>
                    <measurement group_id="O3" value="24.6"/>
                    <measurement group_id="O4" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20, week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="39.4"/>
                    <measurement group_id="O3" value="23.2"/>
                    <measurement group_id="O4" value="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20, week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="38.0"/>
                    <measurement group_id="O3" value="18.1"/>
                    <measurement group_id="O4" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20, week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="30.7"/>
                    <measurement group_id="O3" value="18.1"/>
                    <measurement group_id="O4" value="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50, week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="0.7"/>
                    <measurement group_id="O4" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50, week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50, week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4"/>
                    <measurement group_id="O2" value="10.2"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50, week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="15.3"/>
                    <measurement group_id="O3" value="10.1"/>
                    <measurement group_id="O4" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50, week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="13.1"/>
                    <measurement group_id="O3" value="10.1"/>
                    <measurement group_id="O4" value="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50, week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="9.4"/>
                    <measurement group_id="O4" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50, week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="8.0"/>
                    <measurement group_id="O4" value="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50, week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="16.8"/>
                    <measurement group_id="O3" value="9.4"/>
                    <measurement group_id="O4" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70, week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70, week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70, week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70, week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="4.4"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70, week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70, week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="8.0"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70, week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="5.8"/>
                    <measurement group_id="O4" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70, week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="10.2"/>
                    <measurement group_id="O3" value="5.1"/>
                    <measurement group_id="O4" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data</title>
        <description>ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient’s assessment of RA pain, patient’s global assessment of disease activity, physician’s global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20, ACR50 and ACR70 response results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
        <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52</time_frame>
        <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Non-responder - AIN457 75 mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 16.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Non-responder - AIN457 150 mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 16.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Responder - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Responder - AIN457 150mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 24.</description>
          </group>
          <group group_id="O9">
            <title>Abatacept Responders</title>
            <description>Abatacept responders remained on abatacept (from 500 to 1000 mg iv based on weight).</description>
          </group>
          <group group_id="O10">
            <title>Abatacept Non-respnders - AIN457 75mg</title>
            <description>Participants switched from abatacept to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O11">
            <title>Abatacept Non-responders - AIN457 150mg</title>
            <description>Participants switched from abatacept to AIN457 150 mg starting at week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving ACR20, ACR 50 and ACR 70 - Observed Data</title>
          <description>ACR20, ACR 50 and ACR 70 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20%, 50% and/or 70% improvement, respectively, in tender 68-joint count, swollen 66-joint count and at least 3 of the following 5 measures: patient’s assessment of RA pain, patient’s global assessment of disease activity, physician’s global assessment of disease activity, subject self-assessed disability (Health Assessment Questionnaire [HAQ-DI] score), and/or acute phase reactant (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR). The ACR20, ACR50 and ACR70 response results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
          <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="138"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="101"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR20,wk 1,n=132,129,130,130,39,35,21,22,96,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="7.7"/>
                    <measurement group_id="O4" value="11.5"/>
                    <measurement group_id="O5" value="5.1"/>
                    <measurement group_id="O6" value="5.7"/>
                    <measurement group_id="O7" value="14.3"/>
                    <measurement group_id="O8" value="13.6"/>
                    <measurement group_id="O9" value="14.6"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk 2,n=131,130,134,134,39,36,23,22,99,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="22.3"/>
                    <measurement group_id="O3" value="12.7"/>
                    <measurement group_id="O4" value="25.4"/>
                    <measurement group_id="O5" value="2.6"/>
                    <measurement group_id="O6" value="11.1"/>
                    <measurement group_id="O7" value="34.8"/>
                    <measurement group_id="O8" value="13.6"/>
                    <measurement group_id="O9" value="29.3"/>
                    <measurement group_id="O10" value="11.8"/>
                    <measurement group_id="O11" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk 4,n=133,132,131,129,39,39,23,21,93,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1"/>
                    <measurement group_id="O2" value="28.0"/>
                    <measurement group_id="O3" value="22.9"/>
                    <measurement group_id="O4" value="34.1"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="12.8"/>
                    <measurement group_id="O7" value="43.5"/>
                    <measurement group_id="O8" value="42.9"/>
                    <measurement group_id="O9" value="41.9"/>
                    <measurement group_id="O10" value="17.6"/>
                    <measurement group_id="O11" value="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk 8,n=132,127,131,131,39,39,23,22,95,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6"/>
                    <measurement group_id="O2" value="44.9"/>
                    <measurement group_id="O3" value="22.1"/>
                    <measurement group_id="O4" value="52.7"/>
                    <measurement group_id="O5" value="17.9"/>
                    <measurement group_id="O6" value="12.8"/>
                    <measurement group_id="O7" value="39.1"/>
                    <measurement group_id="O8" value="31.8"/>
                    <measurement group_id="O9" value="61.1"/>
                    <measurement group_id="O10" value="29.4"/>
                    <measurement group_id="O11" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk 12,n=130,115,123,129,39,37,23,21,94,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="27.6"/>
                    <measurement group_id="O4" value="51.2"/>
                    <measurement group_id="O5" value="15.4"/>
                    <measurement group_id="O6" value="16.2"/>
                    <measurement group_id="O7" value="47.8"/>
                    <measurement group_id="O8" value="52.4"/>
                    <measurement group_id="O9" value="62.8"/>
                    <measurement group_id="O10" value="17.6"/>
                    <measurement group_id="O11" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk 16,n=126,118,116,129,36,37,21,22,94,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="45.8"/>
                    <measurement group_id="O3" value="27.6"/>
                    <measurement group_id="O4" value="55.8"/>
                    <measurement group_id="O5" value="2.8"/>
                    <measurement group_id="O6" value="2.7"/>
                    <measurement group_id="O7" value="76.2"/>
                    <measurement group_id="O8" value="63.6"/>
                    <measurement group_id="O9" value="76.6"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk 20,n=122,114,119,126,38,37,23,21,91,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3"/>
                    <measurement group_id="O2" value="51.8"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="57.9"/>
                    <measurement group_id="O5" value="42.1"/>
                    <measurement group_id="O6" value="29.7"/>
                    <measurement group_id="O7" value="60.9"/>
                    <measurement group_id="O8" value="47.6"/>
                    <measurement group_id="O9" value="73.6"/>
                    <measurement group_id="O10" value="6.3"/>
                    <measurement group_id="O11" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk 24,n=117,110,117,121,38,36,21,22,87,16,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3"/>
                    <measurement group_id="O2" value="48.2"/>
                    <measurement group_id="O3" value="40.2"/>
                    <measurement group_id="O4" value="57.9"/>
                    <measurement group_id="O5" value="26.3"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="57.1"/>
                    <measurement group_id="O8" value="59.1"/>
                    <measurement group_id="O9" value="69.0"/>
                    <measurement group_id="O10" value="31.3"/>
                    <measurement group_id="O11" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk28,n=115,103,na,na,33,35,21,21,86,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8"/>
                    <measurement group_id="O2" value="65.0"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="37.1"/>
                    <measurement group_id="O7" value="71.4"/>
                    <measurement group_id="O8" value="90.5"/>
                    <measurement group_id="O9" value="74.4"/>
                    <measurement group_id="O10" value="41.2"/>
                    <measurement group_id="O11" value="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk32,n=104,97,na,na,33,30,21,19,87,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7"/>
                    <measurement group_id="O2" value="61.9"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="51.5"/>
                    <measurement group_id="O6" value="36.7"/>
                    <measurement group_id="O7" value="81.0"/>
                    <measurement group_id="O8" value="68.4"/>
                    <measurement group_id="O9" value="74.7"/>
                    <measurement group_id="O10" value="23.5"/>
                    <measurement group_id="O11" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk36,n=102,93,na,na,30,30,21,20,85,18,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9"/>
                    <measurement group_id="O2" value="53.8"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="46.7"/>
                    <measurement group_id="O6" value="56.7"/>
                    <measurement group_id="O7" value="85.7"/>
                    <measurement group_id="O8" value="65.0"/>
                    <measurement group_id="O9" value="77.6"/>
                    <measurement group_id="O10" value="27.8"/>
                    <measurement group_id="O11" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk40,n=96,90,na,na,28,28,21,19,85,15,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1"/>
                    <measurement group_id="O2" value="61.1"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="53.6"/>
                    <measurement group_id="O6" value="53.6"/>
                    <measurement group_id="O7" value="85.7"/>
                    <measurement group_id="O8" value="73.7"/>
                    <measurement group_id="O9" value="71.8"/>
                    <measurement group_id="O10" value="40.0"/>
                    <measurement group_id="O11" value="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk44,n=97,90,na,na,28,27,20,18,84,15,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7"/>
                    <measurement group_id="O2" value="61.1"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="50.0"/>
                    <measurement group_id="O6" value="55.6"/>
                    <measurement group_id="O7" value="85.0"/>
                    <measurement group_id="O8" value="77.8"/>
                    <measurement group_id="O9" value="77.4"/>
                    <measurement group_id="O10" value="33.3"/>
                    <measurement group_id="O11" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk48,n=94,89,na,na,28,26,18,19,77,12,14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4"/>
                    <measurement group_id="O2" value="68.5"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="53.6"/>
                    <measurement group_id="O6" value="61.5"/>
                    <measurement group_id="O7" value="72.2"/>
                    <measurement group_id="O8" value="57.9"/>
                    <measurement group_id="O9" value="71.4"/>
                    <measurement group_id="O10" value="25.0"/>
                    <measurement group_id="O11" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR20,wk52,n=92,88,na,na,28,26,20,18,79,15,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="39.3"/>
                    <measurement group_id="O6" value="57.7"/>
                    <measurement group_id="O7" value="75.0"/>
                    <measurement group_id="O8" value="88.9"/>
                    <measurement group_id="O9" value="74.7"/>
                    <measurement group_id="O10" value="40.0"/>
                    <measurement group_id="O11" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk1,n=132,129,130,130,39,35,21,22,96,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="3.1"/>
                    <measurement group_id="O3" value="0.8"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="4.8"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="1.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk2,n=131,130,134,134,39,36,23,22,99,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="3.0"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="13.0"/>
                    <measurement group_id="O8" value="4.5"/>
                    <measurement group_id="O9" value="3.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk4,n=133,132,131,129,39,39,23,21,93,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                    <measurement group_id="O2" value="10.6"/>
                    <measurement group_id="O3" value="3.1"/>
                    <measurement group_id="O4" value="7.8"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="8.7"/>
                    <measurement group_id="O8" value="9.5"/>
                    <measurement group_id="O9" value="10.8"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk8,n=132,127,131,131,39,39,23,22,95,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="16.5"/>
                    <measurement group_id="O3" value="10.7"/>
                    <measurement group_id="O4" value="20.6"/>
                    <measurement group_id="O5" value="5.1"/>
                    <measurement group_id="O6" value="5.1"/>
                    <measurement group_id="O7" value="34.8"/>
                    <measurement group_id="O8" value="9.1"/>
                    <measurement group_id="O9" value="25.3"/>
                    <measurement group_id="O10" value="11.8"/>
                    <measurement group_id="O11" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk12,n=130,115,123,129,39,37,23,21,94,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0"/>
                    <measurement group_id="O2" value="15.7"/>
                    <measurement group_id="O3" value="11.4"/>
                    <measurement group_id="O4" value="24.8"/>
                    <measurement group_id="O5" value="2.6"/>
                    <measurement group_id="O6" value="8.1"/>
                    <measurement group_id="O7" value="21.7"/>
                    <measurement group_id="O8" value="23.8"/>
                    <measurement group_id="O9" value="30.9"/>
                    <measurement group_id="O10" value="5.9"/>
                    <measurement group_id="O11" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk16,n=126,118,116,129,36,37,21,22,94,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="23.7"/>
                    <measurement group_id="O3" value="11.2"/>
                    <measurement group_id="O4" value="26.4"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="38.1"/>
                    <measurement group_id="O8" value="22.7"/>
                    <measurement group_id="O9" value="36.2"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk20,n=122,114,119,126,38,37,23,21,91,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="21.9"/>
                    <measurement group_id="O3" value="12.6"/>
                    <measurement group_id="O4" value="31.7"/>
                    <measurement group_id="O5" value="7.9"/>
                    <measurement group_id="O6" value="2.7"/>
                    <measurement group_id="O7" value="34.8"/>
                    <measurement group_id="O8" value="14.3"/>
                    <measurement group_id="O9" value="40.7"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk24,n=117,110,117,121,38,36,21,22,87,16,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="14.5"/>
                    <measurement group_id="O4" value="33.1"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="11.1"/>
                    <measurement group_id="O7" value="38.1"/>
                    <measurement group_id="O8" value="22.7"/>
                    <measurement group_id="O9" value="44.8"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk28,n=115,103,na,na,33,35,21,21,86,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="6.1"/>
                    <measurement group_id="O6" value="8.6"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="41.9"/>
                    <measurement group_id="O10" value="23.5"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk32,n=104,97,na,na,33,30,21,19,87,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2"/>
                    <measurement group_id="O2" value="32.0"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="6.1"/>
                    <measurement group_id="O6" value="13.3"/>
                    <measurement group_id="O7" value="42.9"/>
                    <measurement group_id="O8" value="31.6"/>
                    <measurement group_id="O9" value="47.1"/>
                    <measurement group_id="O10" value="5.9"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk36,n=102,93,na,na,30,30,21,20,85,18,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="16.7"/>
                    <measurement group_id="O7" value="28.6"/>
                    <measurement group_id="O8" value="20.0"/>
                    <measurement group_id="O9" value="47.1"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk40,n=96,90,na,na,28,28,21,19,85,15,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O6" value="28.6"/>
                    <measurement group_id="O7" value="38.1"/>
                    <measurement group_id="O8" value="26.3"/>
                    <measurement group_id="O9" value="45.9"/>
                    <measurement group_id="O10" value="20.0"/>
                    <measurement group_id="O11" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk44,n=97,90,na,na,28,27,20,18,84,15,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.8"/>
                    <measurement group_id="O2" value="30.0"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="7.1"/>
                    <measurement group_id="O6" value="29.6"/>
                    <measurement group_id="O7" value="35.0"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="50.0"/>
                    <measurement group_id="O10" value="13.3"/>
                    <measurement group_id="O11" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk48,n=94,89,na,na,28,26,18,19,77,12,14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5"/>
                    <measurement group_id="O2" value="42.7"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O6" value="23.1"/>
                    <measurement group_id="O7" value="38.9"/>
                    <measurement group_id="O8" value="26.3"/>
                    <measurement group_id="O9" value="48.1"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50,wk52,n=92,88,na,na,28,26,20,18,79,15,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="45.5"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="10.7"/>
                    <measurement group_id="O6" value="26.9"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="44.4"/>
                    <measurement group_id="O9" value="51.9"/>
                    <measurement group_id="O10" value="20.0"/>
                    <measurement group_id="O11" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk1,n=132,129,130,130,39,35,21,22,96,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.8"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="1.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk2,n=131,130,134,134,39,36,23,22,99,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="0.7"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="4.3"/>
                    <measurement group_id="O8" value="4.5"/>
                    <measurement group_id="O9" value="1.0"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk4,n=133,132,131,129,39,39,23,21,93,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="4.3"/>
                    <measurement group_id="O8" value="4.8"/>
                    <measurement group_id="O9" value="2.2"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk8,n=132,127,131,131,39,39,23,22,95,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="4.7"/>
                    <measurement group_id="O3" value="3.1"/>
                    <measurement group_id="O4" value="6.1"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="2.6"/>
                    <measurement group_id="O7" value="13.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="7.4"/>
                    <measurement group_id="O10" value="5.9"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk12,n=130,115,123,129,39,37,23,21,94,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="3.5"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="10.9"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="13.0"/>
                    <measurement group_id="O8" value="4.8"/>
                    <measurement group_id="O9" value="14.9"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk16,n=126,118,116,129,36,37,21,22,94,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="9.3"/>
                    <measurement group_id="O3" value="3.4"/>
                    <measurement group_id="O4" value="10.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="14.3"/>
                    <measurement group_id="O8" value="4.5"/>
                    <measurement group_id="O9" value="13.8"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk20,n=122,114,119,126,38,37,23,21,91,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="6.7"/>
                    <measurement group_id="O4" value="11.1"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="21.7"/>
                    <measurement group_id="O8" value="14.3"/>
                    <measurement group_id="O9" value="15.4"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk24,n=117,110,117,121,38,36,21,22,87,16,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="12.7"/>
                    <measurement group_id="O3" value="8.5"/>
                    <measurement group_id="O4" value="14.9"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="23.8"/>
                    <measurement group_id="O8" value="9.1"/>
                    <measurement group_id="O9" value="19.5"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk28,n=115,103,na,na,33,35,21,21,86,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="2.9"/>
                    <measurement group_id="O7" value="14.3"/>
                    <measurement group_id="O8" value="14.3"/>
                    <measurement group_id="O9" value="17.4"/>
                    <measurement group_id="O10" value="5.9"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk32,n=104,97,na,na,33,30,21,19,87,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="3.3"/>
                    <measurement group_id="O7" value="19.0"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="21.8"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk36,n=102,93,na,na,30,30,21,20,85,18,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="11.8"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="3.3"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="23.8"/>
                    <measurement group_id="O8" value="0.0"/>
                    <measurement group_id="O9" value="23.5"/>
                    <measurement group_id="O10" value="11.1"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk40,n=96,90,na,na,28,28,21,19,85,15,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="7.1"/>
                    <measurement group_id="O6" value="10.7"/>
                    <measurement group_id="O7" value="19.0"/>
                    <measurement group_id="O8" value="10.5"/>
                    <measurement group_id="O9" value="21.2"/>
                    <measurement group_id="O10" value="13.3"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk44,n=97,90,na,na,28,27,20,18,84,15,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4"/>
                    <measurement group_id="O2" value="18.9"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="11.1"/>
                    <measurement group_id="O7" value="25.0"/>
                    <measurement group_id="O8" value="11.1"/>
                    <measurement group_id="O9" value="26.2"/>
                    <measurement group_id="O10" value="6.7"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk48,n=94,89,na,na,28,26,18,19,77,12,14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="20.2"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="3.6"/>
                    <measurement group_id="O6" value="15.4"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="10.5"/>
                    <measurement group_id="O9" value="27.3"/>
                    <measurement group_id="O10" value="0.0"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70,wk52,n=92,88,na,na,28,26,20,18,79,15,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="19.3"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="7.7"/>
                    <measurement group_id="O7" value="30.0"/>
                    <measurement group_id="O8" value="16.7"/>
                    <measurement group_id="O9" value="22.8"/>
                    <measurement group_id="O10" value="13.3"/>
                    <measurement group_id="O11" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)</title>
        <description>The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, &quot;are you able to...&quot; perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.</description>
        <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <population>Participants from the full analysis set were considered for this analysis. For Placebo and Abatacept participants, data collected after treatment switch was treated as missing, as were missing values for all treatment groups.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI - Using Mixed Model Repeated Measures (MMRM)</title>
          <description>The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, &quot;are you able to...&quot; perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set were considered for this analysis. For Placebo and Abatacept participants, data collected after treatment switch was treated as missing, as were missing values for all treatment groups.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 1, n=132,129,130,129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.032"/>
                    <measurement group_id="O2" value="-0.21" spread="0.032"/>
                    <measurement group_id="O3" value="-0.08" spread="0.032"/>
                    <measurement group_id="O4" value="-0.19" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 2, n=131,130,134,133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.036"/>
                    <measurement group_id="O2" value="-0.25" spread="0.036"/>
                    <measurement group_id="O3" value="-0.16" spread="0.036"/>
                    <measurement group_id="O4" value="-0.26" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4, n=133,133,131,130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.039"/>
                    <measurement group_id="O2" value="-0.31" spread="0.040"/>
                    <measurement group_id="O3" value="-0.17" spread="0.040"/>
                    <measurement group_id="O4" value="-0.36" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8, n=132,127,131,130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.042"/>
                    <measurement group_id="O2" value="-0.32" spread="0.043"/>
                    <measurement group_id="O3" value="-0.17" spread="0.043"/>
                    <measurement group_id="O4" value="-0.46" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12, n=130,114,123,129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.046"/>
                    <measurement group_id="O2" value="-0.33" spread="0.047"/>
                    <measurement group_id="O3" value="-0.18" spread="0.047"/>
                    <measurement group_id="O4" value="-0.51" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16, n=127,118,116,129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.048"/>
                    <measurement group_id="O2" value="-0.37" spread="0.049"/>
                    <measurement group_id="O3" value="-0.22" spread="0.049"/>
                    <measurement group_id="O4" value="-0.52" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20, n=122,114,47,92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.051"/>
                    <measurement group_id="O2" value="-0.42" spread="0.052"/>
                    <measurement group_id="O3" value="-0.21" spread="0.066"/>
                    <measurement group_id="O4" value="-0.57" spread="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24, n=117,110,44,86</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.049"/>
                    <measurement group_id="O2" value="-0.39" spread="0.051"/>
                    <measurement group_id="O3" value="-0.26" spread="0.065"/>
                    <measurement group_id="O4" value="-0.61" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI - Observed Data</title>
        <description>The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, &quot;are you able to...&quot; perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement. The HAQ-DI results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
        <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52</time_frame>
        <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Non-responder - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 16.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Non-responder - AIN457 150mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 16.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Responder - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Responder - AIN457 150mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 24.</description>
          </group>
          <group group_id="O9">
            <title>Abatacept Responders</title>
            <description>Abatacept responders remained on abatacept (from 500 to 1000 mg iv based on weight).</description>
          </group>
          <group group_id="O10">
            <title>Abatacept Non-responders - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O11">
            <title>Abatacept Non-responders - AIN457 150mg</title>
            <description>Participants switched from abatacept to AIN457 150 mg starting at week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI - Observed Data</title>
          <description>The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, &quot;are you able to...&quot; perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement. The HAQ-DI results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
          <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="138"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="101"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>wk1,n=132,129,130,129,39,35,21,22,95,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.225" spread="0.3766"/>
                    <measurement group_id="O2" value="-0.215" spread="0.4095"/>
                    <measurement group_id="O3" value="-0.101" spread="0.3186"/>
                    <measurement group_id="O4" value="-0.194" spread="0.4290"/>
                    <measurement group_id="O5" value="-0.119" spread="0.2896"/>
                    <measurement group_id="O6" value="-0.079" spread="0.3093"/>
                    <measurement group_id="O7" value="-0.125" spread="0.4257"/>
                    <measurement group_id="O8" value="-0.153" spread="0.2468"/>
                    <measurement group_id="O9" value="-0.232" spread="0.4551"/>
                    <measurement group_id="O10" value="-0.081" spread="0.3616"/>
                    <measurement group_id="O11" value="-0.096" spread="0.3047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk2,n=131,130,134,133,39,36,23,22,133,98,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.215" spread="0.3877"/>
                    <measurement group_id="O2" value="-0.239" spread="0.4885"/>
                    <measurement group_id="O3" value="-0.191" spread="0.4340"/>
                    <measurement group_id="O4" value="-0.254" spread="0.4520"/>
                    <measurement group_id="O5" value="-0.122" spread="0.2605"/>
                    <measurement group_id="O6" value="-0.176" spread="0.4631"/>
                    <measurement group_id="O7" value="-0.380" spread="0.5063"/>
                    <measurement group_id="O8" value="-0.250" spread="0.5015"/>
                    <measurement group_id="O9" value="-0.300" spread="0.4693"/>
                    <measurement group_id="O10" value="-0.132" spread="0.3630"/>
                    <measurement group_id="O11" value="-0.118" spread="0.3987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk4,n=133,133,131,130,39,39,23,21,94,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.299" spread="0.4551"/>
                    <measurement group_id="O2" value="-0.300" spread="0.5184"/>
                    <measurement group_id="O3" value="-0.214" spread="0.4492"/>
                    <measurement group_id="O4" value="-0.368" spread="0.5130"/>
                    <measurement group_id="O5" value="-0.077" spread="0.3634"/>
                    <measurement group_id="O6" value="-0.224" spread="0.4968"/>
                    <measurement group_id="O7" value="-0.364" spread="0.5627"/>
                    <measurement group_id="O8" value="-0.310" spread="0.3103"/>
                    <measurement group_id="O9" value="-0.445" spread="0.5245"/>
                    <measurement group_id="O10" value="-0.110" spread="0.3505"/>
                    <measurement group_id="O11" value="-0.217" spread="0.4874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk8,n=132,127,131,130,39,39,23,22,94,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.277" spread="0.5062"/>
                    <measurement group_id="O2" value="-0.309" spread="0.5175"/>
                    <measurement group_id="O3" value="-0.217" spread="0.5457"/>
                    <measurement group_id="O4" value="-0.463" spread="0.5182"/>
                    <measurement group_id="O5" value="-0.186" spread="0.5097"/>
                    <measurement group_id="O6" value="-0.128" spread="0.5077"/>
                    <measurement group_id="O7" value="-0.543" spread="0.6313"/>
                    <measurement group_id="O8" value="-0.176" spread="0.4782"/>
                    <measurement group_id="O9" value="-0.543" spread="0.5289"/>
                    <measurement group_id="O10" value="-0.206" spread="0.4900"/>
                    <measurement group_id="O11" value="-0.303" spread="0.3780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>wk12,n=130,114,123,129,39,37,23,21,94,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.287" spread="0.5384"/>
                    <measurement group_id="O2" value="-0.307" spread="0.5488"/>
                    <measurement group_id="O3" value="-0.241" spread="0.5152"/>
                    <measurement group_id="O4" value="-0.508" spread="0.6369"/>
                    <measurement group_id="O5" value="-0.109" spread="0.4783"/>
                    <measurement group_id="O6" value="-0.179" spread="0.5133"/>
                    <measurement group_id="O7" value="-0.451" spread="0.6167"/>
                    <measurement group_id="O8" value="-0.381" spread="0.3982"/>
                    <measurement group_id="O9" value="-0.622" spread="0.6520"/>
                    <measurement group_id="O10" value="-0.221" spread="0.4274"/>
                    <measurement group_id="O11" value="-0.181" spread="0.5376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk16,n=127,118,116,129,36,37,21,22,94,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.294" spread="0.5236"/>
                    <measurement group_id="O2" value="-0.355" spread="0.6217"/>
                    <measurement group_id="O3" value="-0.279" spread="0.5493"/>
                    <measurement group_id="O4" value="-0.535" spread="0.6418"/>
                    <measurement group_id="O5" value="-0.167" spread="0.5295"/>
                    <measurement group_id="O6" value="-0.111" spread="0.4591"/>
                    <measurement group_id="O7" value="-0.565" spread="0.5356"/>
                    <measurement group_id="O8" value="-0.472" spread="0.5988"/>
                    <measurement group_id="O9" value="-0.660" spread="0.6590"/>
                    <measurement group_id="O10" value="-0.195" spread="0.4281"/>
                    <measurement group_id="O11" value="-0.204" spread="0.4827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20,n=122,114,119,125,38,37,23,21,90,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.333" spread="0.5111"/>
                    <measurement group_id="O2" value="-0.402" spread="0.6429"/>
                    <measurement group_id="O3" value="-0.319" spread="0.5637"/>
                    <measurement group_id="O4" value="-0.583" spread="0.6654"/>
                    <measurement group_id="O5" value="-0.237" spread="0.4756"/>
                    <measurement group_id="O6" value="-0.179" spread="0.5158"/>
                    <measurement group_id="O7" value="-0.543" spread="0.5325"/>
                    <measurement group_id="O8" value="-0.470" spread="0.7309"/>
                    <measurement group_id="O9" value="-0.699" spread="0.6849"/>
                    <measurement group_id="O10" value="-0.086" spread="0.3972"/>
                    <measurement group_id="O11" value="-0.454" spread="0.5436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk24,n=117,110,117,120,38,36,21,22,86,16,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.268" spread="0.4930"/>
                    <measurement group_id="O2" value="-0.405" spread="0.5767"/>
                    <measurement group_id="O3" value="0.346" spread="0.5941"/>
                    <measurement group_id="O4" value="-0.590" spread="0.6872"/>
                    <measurement group_id="O5" value="-0.257" spread="0.4730"/>
                    <measurement group_id="O6" value="-0.253" spread="0.6502"/>
                    <measurement group_id="O7" value="-0.589" spread="0.5648"/>
                    <measurement group_id="O8" value="-0.420" spread="0.6732"/>
                    <measurement group_id="O9" value="-0.744" spread="0.6787"/>
                    <measurement group_id="O10" value="-0.180" spread="0.4257"/>
                    <measurement group_id="O11" value="-0.215" spread="0.6443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk28,n=115,102,na,na,33,35,21,21,86,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.304" spread="0.5342"/>
                    <measurement group_id="O2" value="-0.439" spread="0.5780"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-0.345" spread="0.5880"/>
                    <measurement group_id="O6" value="-0.336" spread="0.5846"/>
                    <measurement group_id="O7" value="-0.625" spread="0.4809"/>
                    <measurement group_id="O8" value="-0.601" spread="0.5571"/>
                    <measurement group_id="O9" value="-0.689" spread="0.6428"/>
                    <measurement group_id="O10" value="-0.309" spread="0.5522"/>
                    <measurement group_id="O11" value="-0.303" spread="0.5882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32,n=104,97,na,na,33,30,21,19,87,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.358" spread="0.4964"/>
                    <measurement group_id="O2" value="-0.505" spread="0.5759"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-0.284" spread="0.4627"/>
                    <measurement group_id="O6" value="-0.300" spread="0.5039"/>
                    <measurement group_id="O7" value="-0.679" spread="0.5414"/>
                    <measurement group_id="O8" value="-0.546" spread="0.5998"/>
                    <measurement group_id="O9" value="-0.741" spread="0.6909"/>
                    <measurement group_id="O10" value="-0.228" spread="0.5612"/>
                    <measurement group_id="O11" value="-0.375" spread="0.7315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk36,n=102,93,na,na,30,30,21,19,84,18,16,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.339" spread="0.5687"/>
                    <measurement group_id="O2" value="-0.430" spread="0.5573"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-0.368" spread="0.5397"/>
                    <measurement group_id="O6" value="-0.383" spread="0.4500"/>
                    <measurement group_id="O7" value="-0.607" spread="0.5538"/>
                    <measurement group_id="O8" value="-0.474" spread="0.6032"/>
                    <measurement group_id="O9" value="-0.756" spread="0.6844"/>
                    <measurement group_id="O10" value="-0.285" spread="0.5891"/>
                    <measurement group_id="O11" value="-0.430" spread="0.6723"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk40,n=96,89,na,na,28,28,21,19,84,15,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.424" spread="0.5967"/>
                    <measurement group_id="O2" value="-0.440" spread="0.5416"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-0.522" spread="0.6805"/>
                    <measurement group_id="O6" value="-0.391" spread="0.5446"/>
                    <measurement group_id="O7" value="-0.571" spread="0.5736"/>
                    <measurement group_id="O8" value="-0.539" spread="0.6998"/>
                    <measurement group_id="O9" value="-0.763" spread="0.6750"/>
                    <measurement group_id="O10" value="-0.242" spread="0.6312"/>
                    <measurement group_id="O11" value="-0.390" spread="0.6523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk44,n=97,90,na,na,28,27,20,18,84,15,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.331" spread="0.5871"/>
                    <measurement group_id="O2" value="-0.449" spread="0.5427"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-0.277" spread="0.6377"/>
                    <measurement group_id="O6" value="-0.523" spread="0.6587"/>
                    <measurement group_id="O7" value="-0.638" spread="0.5144"/>
                    <measurement group_id="O8" value="-0.514" spread="0.7752"/>
                    <measurement group_id="O9" value="-0.781" spread="0.7252"/>
                    <measurement group_id="O10" value="-0.308" spread="0.6319"/>
                    <measurement group_id="O11" value="-0.203" spread="0.7917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk48,n-94,89,na,na,28,26,19,19,76,12,14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.303" spread="0.5062"/>
                    <measurement group_id="O2" value="-0.483" spread="0.5459"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-0.348" spread="0.5886"/>
                    <measurement group_id="O6" value="-0.413" spread="0.5698"/>
                    <measurement group_id="O7" value="-0.605" spread="0.6113"/>
                    <measurement group_id="O8" value="-0.454" spread="0.5547"/>
                    <measurement group_id="O9" value="-0.798" spread="0.6481"/>
                    <measurement group_id="O10" value="-0.229" spread="0.6546"/>
                    <measurement group_id="O11" value="-0.286" spread="0.7618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk52,n=92,87,na,na,28,26,20,18,79,15,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.341" spread="0.5428"/>
                    <measurement group_id="O2" value="-0.516" spread="0.6036"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-0.402" spread="0.5436"/>
                    <measurement group_id="O6" value="-0.351" spread="0.6335"/>
                    <measurement group_id="O7" value="-0.606" spread="0.6492"/>
                    <measurement group_id="O8" value="-0.569" spread="0.7126"/>
                    <measurement group_id="O9" value="-0.788" spread="0.6853"/>
                    <measurement group_id="O10" value="-0.392" spread="0.5216"/>
                    <measurement group_id="O11" value="-0.258" spread="0.8298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM</title>
        <description>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient’s Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.</description>
        <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <population>Participants from the full analysis set were considered for the analysis. For Placebo and Abatacept participants, data collected after treatment switch was treated as missing, as were missing values for all treatment groups</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Using MMRM</title>
          <description>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient’s Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set were considered for the analysis. For Placebo and Abatacept participants, data collected after treatment switch was treated as missing, as were missing values for all treatment groups</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 1, n=131,129,130,129</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="0.069"/>
                    <measurement group_id="O2" value="-0.73" spread="0.069"/>
                    <measurement group_id="O3" value="-0.22" spread="0.069"/>
                    <measurement group_id="O4" value="-0.50" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 2, n=131,127,132,133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.080"/>
                    <measurement group_id="O2" value="-0.90" spread="0.081"/>
                    <measurement group_id="O3" value="-0.35" spread="0.080"/>
                    <measurement group_id="O4" value="-0.78" spread="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4, n=130,131,138,138</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="0.090"/>
                    <measurement group_id="O2" value="-1.11" spread="0.090"/>
                    <measurement group_id="O3" value="-0.48" spread="0.090"/>
                    <measurement group_id="O4" value="-1.11" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8, n=130,126,130,130</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="0.093"/>
                    <measurement group_id="O2" value="-1.23" spread="0.094"/>
                    <measurement group_id="O3" value="-0.61" spread="0.093"/>
                    <measurement group_id="O4" value="-1.55" spread="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12, n=130,114,123,128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="0.097"/>
                    <measurement group_id="O2" value="-1.36" spread="0.102"/>
                    <measurement group_id="O3" value="-0.73" spread="0.100"/>
                    <measurement group_id="O4" value="-1.78" spread="0.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16, n=126,116,114,127</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" spread="0.108"/>
                    <measurement group_id="O2" value="-1.40" spread="0.112"/>
                    <measurement group_id="O3" value="-0.57" spread="0.112"/>
                    <measurement group_id="O4" value="-1.71" spread="0.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20, n=121,114,47,92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="0.108"/>
                    <measurement group_id="O2" value="-1.49" spread="0.111"/>
                    <measurement group_id="O3" value="-0.89" spread="0.146"/>
                    <measurement group_id="O4" value="-1.96" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24, n=116,108,44,84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="0.115"/>
                    <measurement group_id="O2" value="-1.47" spread="0.119"/>
                    <measurement group_id="O3" value="-1.02" spread="0.163"/>
                    <measurement group_id="O4" value="-2.07" spread="0.128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data</title>
        <description>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient’s Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement. The DAS28-CRP results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
        <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52</time_frame>
        <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Non-responder - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 16.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Non-responder - AIN457 150mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 16.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Responder - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Responder - AIN457 150mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 24.</description>
          </group>
          <group group_id="O9">
            <title>Abatacept Responders</title>
            <description>Abatacept responders remained on abatacept (from 500 to 1000 mg iv based on weight).</description>
          </group>
          <group group_id="O10">
            <title>Abatacept Non-responders - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O11">
            <title>Abatacept Non-responders - AIN457 150mg</title>
            <description>Participants switched from abatacept to AIN457 150 mg starting at week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Utilizing CRP (DAS28-CRP) - Observed Data</title>
          <description>The DAS28 is a measure of disease activity in RA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient’s Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. A negative change from baseline indicates improvement. The DAS28-CRP results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
          <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="138"/>
                <count group_id="O9" value="101"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk1,n=131,129,130,129,39,35,21,22, 95,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.886" spread="0.9784"/>
                    <measurement group_id="O2" value="-0.759" spread="0.8654"/>
                    <measurement group_id="O3" value="-0.211" spread="0.6877"/>
                    <measurement group_id="O4" value="-0.502" spread="0.7539"/>
                    <measurement group_id="O5" value="-0.147" spread="0.5527"/>
                    <measurement group_id="O6" value="-0.141" spread="0.7095"/>
                    <measurement group_id="O7" value="-0.572" spread="0.7856"/>
                    <measurement group_id="O8" value="-0.235" spread="0.7699"/>
                    <measurement group_id="O9" value="-0.577" spread="0.7924"/>
                    <measurement group_id="O10" value="-0.361" spread="0.3578"/>
                    <measurement group_id="O11" value="-0.222" spread="0.7695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk2,n=131,127,132,133,39,36,23,21,98,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.909" spread="1.0331"/>
                    <measurement group_id="O2" value="-0.900" spread="1.0284"/>
                    <measurement group_id="O3" value="-0.363" spread="0.8388"/>
                    <measurement group_id="O4" value="-0.755" spread="0.9234"/>
                    <measurement group_id="O5" value="-0.191" spread="0.7331"/>
                    <measurement group_id="O6" value="-0.368" spread="0.7170"/>
                    <measurement group_id="O7" value="-0.835" spread="0.9466"/>
                    <measurement group_id="O8" value="-0.292" spread="0.7448"/>
                    <measurement group_id="O9" value="-0.755" spread="0.9234"/>
                    <measurement group_id="O10" value="-0.882" spread="0.9526"/>
                    <measurement group_id="O11" value="-0.359" spread="0.8980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk4,n=130,131,129,128,39,38,23,21,92,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.163" spread="1.1656"/>
                    <measurement group_id="O2" value="-1.150" spread="1.1942"/>
                    <measurement group_id="O3" value="-0.492" spread="0.8876"/>
                    <measurement group_id="O4" value="-1.095" spread="1.0483"/>
                    <measurement group_id="O5" value="-0.252" spread="0.8116"/>
                    <measurement group_id="O6" value="-0.352" spread="0.7471"/>
                    <measurement group_id="O7" value="-1.034" spread="0.9119"/>
                    <measurement group_id="O8" value="-0.767" spread="0.9661"/>
                    <measurement group_id="O9" value="-1.268" spread="1.0533"/>
                    <measurement group_id="O10" value="-0.595" spread="1.1160"/>
                    <measurement group_id="O11" value="-0.706" spread="0.6999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk8,n=130,126,130,130,39,39,23,22,94,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.181" spread="1.1821"/>
                    <measurement group_id="O2" value="-1.283" spread="1.1678"/>
                    <measurement group_id="O3" value="-0.644" spread="1.1356"/>
                    <measurement group_id="O4" value="-1.541" spread="1.1172"/>
                    <measurement group_id="O5" value="-0.546" spread="1.1597"/>
                    <measurement group_id="O6" value="-0.312" spread="0.9151"/>
                    <measurement group_id="O7" value="-1.403" spread="1.2060"/>
                    <measurement group_id="O8" value="-0.613" spread="0.9772"/>
                    <measurement group_id="O9" value="-1.816" spread="1.0708"/>
                    <measurement group_id="O10" value="-0.834" spread="1.1469"/>
                    <measurement group_id="O11" value="-0.808" spread="0.6444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12,n=130,114,123,128,39,37,23,21,93,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.229" spread="1.1782"/>
                    <measurement group_id="O2" value="-1.402" spread="1.2182"/>
                    <measurement group_id="O3" value="-0.742" spread="1.2330"/>
                    <measurement group_id="O4" value="-1.790" spread="1.2356"/>
                    <measurement group_id="O5" value="-0.311" spread="0.9514"/>
                    <measurement group_id="O6" value="-0.383" spread="1.1765"/>
                    <measurement group_id="O7" value="-1.588" spread="0.9714"/>
                    <measurement group_id="O8" value="-1.330" spread="1.4721"/>
                    <measurement group_id="O9" value="-2.144" spread="1.1028"/>
                    <measurement group_id="O10" value="-0.749" spread="1.0757"/>
                    <measurement group_id="O11" value="-0.945" spread="1.1008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk16,n=126,116,114,128,36,36,21,21,94,15,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.225" spread="1.2866"/>
                    <measurement group_id="O2" value="-1.455" spread="1.3489"/>
                    <measurement group_id="O3" value="-0.592" spread="1.2557"/>
                    <measurement group_id="O4" value="-1.691" spread="1.2979"/>
                    <measurement group_id="O5" value="0.128" spread="0.8579"/>
                    <measurement group_id="O6" value="0.045" spread="0.9145"/>
                    <measurement group_id="O7" value="-2.008" spread="0.8675"/>
                    <measurement group_id="O8" value="-1.503" spread="0.8746"/>
                    <measurement group_id="O9" value="-2.159" spread="1.0767"/>
                    <measurement group_id="O10" value="-0.490" spread="0.8170"/>
                    <measurement group_id="O11" value="-0.322" spread="1.0262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20,n=121,114,,119,125,38,37,23,21,90,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.427" spread="1.3266"/>
                    <measurement group_id="O2" value="-1.569" spread="1.2361"/>
                    <measurement group_id="O3" value="-1.164" spread="1.2087"/>
                    <measurement group_id="O4" value="-1.840" spread="1.4144"/>
                    <measurement group_id="O5" value="-0.683" spread="1.1231"/>
                    <measurement group_id="O6" value="-0.937" spread="1.0966"/>
                    <measurement group_id="O7" value="-2.108" spread="1.0368"/>
                    <measurement group_id="O8" value="-1.399" spread="1.1487"/>
                    <measurement group_id="O9" value="-2.317" spread="1.2549"/>
                    <measurement group_id="O10" value="-0.402" spread="0.9820"/>
                    <measurement group_id="O11" value="-0.792" spread="1.0272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk24,n=116,108,116,117,37,36,21,22,84,15,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.467" spread="1.3116"/>
                    <measurement group_id="O2" value="-1.579" spread="1.3221"/>
                    <measurement group_id="O3" value="-1.248" spread="1.2915"/>
                    <measurement group_id="O4" value="-1.989" spread="1.4717"/>
                    <measurement group_id="O5" value="-0.666" spread="0.9983"/>
                    <measurement group_id="O6" value="-1.140" spread="1.1954"/>
                    <measurement group_id="O7" value="-2.343" spread="1.2649"/>
                    <measurement group_id="O8" value="-1.362" spread="1.2999"/>
                    <measurement group_id="O9" value="-2.435" spread="1.3266"/>
                    <measurement group_id="O10" value="-0.772" spread="1.1656"/>
                    <measurement group_id="O11" value="-0.923" spread="1.2560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk28,n=115,103,na,na,33,35,21,21,86,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.484" spread="1.3216"/>
                    <measurement group_id="O2" value="-1.819" spread="1.3434"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-1.172" spread="1.1602"/>
                    <measurement group_id="O6" value="-1.244" spread="1.2433"/>
                    <measurement group_id="O7" value="-2.117" spread="0.8573"/>
                    <measurement group_id="O8" value="-1.782" spread="1.0655"/>
                    <measurement group_id="O9" value="-2.470" spread="1.2153"/>
                    <measurement group_id="O10" value="-1.137" spread="1.2050"/>
                    <measurement group_id="O11" value="-0.973" spread="1.1034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32,n=103,97,na,na,33,39,23,22,87,17,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.738" spread="1.2783"/>
                    <measurement group_id="O2" value="-1.966" spread="1.1770"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-1.408" spread="1.3855"/>
                    <measurement group_id="O6" value="-1.475" spread="1.1846"/>
                    <measurement group_id="O7" value="-2.363" spread="1.0711"/>
                    <measurement group_id="O8" value="-1.875" spread="0.9807"/>
                    <measurement group_id="O9" value="-2.629" spread="1.3104"/>
                    <measurement group_id="O10" value="-0.961" spread="1.0043"/>
                    <measurement group_id="O11" value="-1.464" spread="1.2025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk36,n=101,92,na,na,30,30,21,20,84,18,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.737" spread="1.4592"/>
                    <measurement group_id="O2" value="-1.820" spread="1.2500"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-1.271" spread="1.4949"/>
                    <measurement group_id="O6" value="-1.444" spread="1.1949"/>
                    <measurement group_id="O7" value="-2.269" spread="1.0688"/>
                    <measurement group_id="O8" value="-1.784" spread="0.9029"/>
                    <measurement group_id="O9" value="-2.642" spread="1.4305"/>
                    <measurement group_id="O10" value="-1.200" spread="1.3228"/>
                    <measurement group_id="O11" value="-1.425" spread="0.9247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk40,n=96,90,na,na,28,28,21,19,84,15,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.742" spread="1.3259"/>
                    <measurement group_id="O2" value="-1.788" spread="1.1333"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-1.354" spread="1.3590"/>
                    <measurement group_id="O6" value="-1.494" spread="1.3243"/>
                    <measurement group_id="O7" value="-2.315" spread="1.0773"/>
                    <measurement group_id="O8" value="-2.134" spread="1.0405"/>
                    <measurement group_id="O9" value="-2.549" spread="1.3305"/>
                    <measurement group_id="O10" value="-1.201" spread="1.5293"/>
                    <measurement group_id="O11" value="-1.612" spread="1.1839"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk44,n=96,88,na,na,28,27,20,18,84,15,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.764" spread="1.3227"/>
                    <measurement group_id="O2" value="-1.932" spread="1.2850"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-1.168" spread="1.2638"/>
                    <measurement group_id="O6" value="-1.858" spread="1.2373"/>
                    <measurement group_id="O7" value="-2.155" spread="0.9488"/>
                    <measurement group_id="O8" value="-2.121" spread="1.1347"/>
                    <measurement group_id="O9" value="-2.697" spread="1.2117"/>
                    <measurement group_id="O10" value="-0.881" spread="1.3337"/>
                    <measurement group_id="O11" value="-1.528" spread="1.2973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk48,n=94,88,na,na,28,26,18,19,76,12,14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.761" spread="1.3152"/>
                    <measurement group_id="O2" value="-2.200" spread="1.3293"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-1.516" spread="1.0635"/>
                    <measurement group_id="O6" value="-1.660" spread="1.1805"/>
                    <measurement group_id="O7" value="-2.259" spread="1.1813"/>
                    <measurement group_id="O8" value="-1.964" spread="1.3404"/>
                    <measurement group_id="O9" value="-2.634" spread="1.2189"/>
                    <measurement group_id="O10" value="-1.013" spread="1.1738"/>
                    <measurement group_id="O11" value="-1.400" spread="1.1985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk52,n=92,86,na,na,28,26,20,18,79,15,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.839" spread="1.3755"/>
                    <measurement group_id="O2" value="-2.109" spread="1.4000"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-1.487" spread="1.0729"/>
                    <measurement group_id="O6" value="-1.690" spread="1.2093"/>
                    <measurement group_id="O7" value="-2.070" spread="0.9984"/>
                    <measurement group_id="O8" value="-2.334" spread="1.1428"/>
                    <measurement group_id="O9" value="-2.676" spread="1.3593"/>
                    <measurement group_id="O10" value="-1.390" spread="1.1884"/>
                    <measurement group_id="O11" value="-0.982" spread="1.1943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in hsCRP - Observed Data</title>
        <description>Blood samples were obtained to identify the presence of inflammation, to determine its severity and to monitor response to treatment. A negative change from baseline indicates improvement. The hsCRP results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
        <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52</time_frame>
        <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Non-responder - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 16.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Non-responder - AIN457 150mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 16.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Responder - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Responder - AIN457 150mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 24.</description>
          </group>
          <group group_id="O9">
            <title>Abatacept Responders</title>
            <description>Abatacept responders remained on abatacept (from 500 to 1000 mg iv based on weight).</description>
          </group>
          <group group_id="O10">
            <title>Abatacept Non-responders - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O11">
            <title>Abatacept Non-responders - AIN457 150mg</title>
            <description>Participants switched from abatacept to AIN457 150 mg starting at week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in hsCRP - Observed Data</title>
          <description>Blood samples were obtained to identify the presence of inflammation, to determine its severity and to monitor response to treatment. A negative change from baseline indicates improvement. The hsCRP results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
          <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="138"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="101"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk1,n=134,130,131,131,39,36,21,22,97,17,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.91" spread="30.815"/>
                    <measurement group_id="O2" value="-10.31" spread="27.754"/>
                    <measurement group_id="O3" value="-0.69" spread="15.521"/>
                    <measurement group_id="O4" value="-5.64" spread="18.550"/>
                    <measurement group_id="O5" value="-0.33" spread="10.430"/>
                    <measurement group_id="O6" value="-0.84" spread="24.777"/>
                    <measurement group_id="O7" value="-0.40" spread="12.244"/>
                    <measurement group_id="O8" value="-1.50" spread="7.541"/>
                    <measurement group_id="O9" value="-6.40" spread="20.458"/>
                    <measurement group_id="O10" value="-2.92" spread="12.405"/>
                    <measurement group_id="O11" value="-4.07" spread="10.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk2,n=133,129,133,135,39,36,23,21,100,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.24" spread="33.209"/>
                    <measurement group_id="O2" value="-11.51" spread="32.139"/>
                    <measurement group_id="O3" value="-2.21" spread="14.501"/>
                    <measurement group_id="O4" value="-6.36" spread="19.416"/>
                    <measurement group_id="O5" value="0.43" spread="15.333"/>
                    <measurement group_id="O6" value="-5.48" spread="17.301"/>
                    <measurement group_id="O7" value="-1.70" spread="11.170"/>
                    <measurement group_id="O8" value="-4.78" spread="10.515"/>
                    <measurement group_id="O9" value="-7.52" spread="20.301"/>
                    <measurement group_id="O10" value="-3.84" spread="13.737"/>
                    <measurement group_id="O11" value="-2.30" spread="19.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk4,n=131,134,129,133,39,38,23,21,97,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.10" spread="20.514"/>
                    <measurement group_id="O2" value="-10.76" spread="33.376"/>
                    <measurement group_id="O3" value="-1.53" spread="19.311"/>
                    <measurement group_id="O4" value="-6.70" spread="20.732"/>
                    <measurement group_id="O5" value="2.23" spread="23.317"/>
                    <measurement group_id="O6" value="-1.94" spread="21.927"/>
                    <measurement group_id="O7" value="-6.47" spread="12.458"/>
                    <measurement group_id="O8" value="-1.95" spread="12.090"/>
                    <measurement group_id="O9" value="-7.53" spread="22.982"/>
                    <measurement group_id="O10" value="-4.42" spread="14.991"/>
                    <measurement group_id="O11" value="-4.50" spread="11.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk8,n=134,128,130,132,39,39,23,22,96,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.18" spread="33.400"/>
                    <measurement group_id="O2" value="-12.94" spread="30.854"/>
                    <measurement group_id="O3" value="-2.94" spread="20.601"/>
                    <measurement group_id="O4" value="-8.48" spread="21.134"/>
                    <measurement group_id="O5" value="-4.72" spread="18.766"/>
                    <measurement group_id="O6" value="-3.28" spread="25.501"/>
                    <measurement group_id="O7" value="0.13" spread="18.061"/>
                    <measurement group_id="O8" value="-1.50" spread="12.839"/>
                    <measurement group_id="O9" value="-10.13" spread="22.724"/>
                    <measurement group_id="O10" value="-.54" spread="14.849"/>
                    <measurement group_id="O11" value="-4.59" spread="16.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12,n=133,119,128,131,39,39,23,22,96,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.41" spread="31.859"/>
                    <measurement group_id="O2" value="-9.66" spread="24.298"/>
                    <measurement group_id="O3" value="-0.69" spread="18.908"/>
                    <measurement group_id="O4" value="-9.72" spread="25.787"/>
                    <measurement group_id="O5" value="2.11" spread="18.312"/>
                    <measurement group_id="O6" value="-2.89" spread="20.763"/>
                    <measurement group_id="O7" value="-2.74" spread="12.899"/>
                    <measurement group_id="O8" value="2.10" spread="22.545"/>
                    <measurement group_id="O9" value="-12.17" spread="25.813"/>
                    <measurement group_id="O10" value="-4.18" spread="16.024"/>
                    <measurement group_id="O11" value="-1.94" spread="31.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk16,n=129,120,121,131,36,38,21,21,96,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.97" spread="33.291"/>
                    <measurement group_id="O2" value="-5.78" spread="25.418"/>
                    <measurement group_id="O3" value="-1.82" spread="20.849"/>
                    <measurement group_id="O4" value="-8.37" spread="22.571"/>
                    <measurement group_id="O5" value="3.92" spread="23.403"/>
                    <measurement group_id="O6" value="-2.13" spread="24.422"/>
                    <measurement group_id="O7" value="-5.67" spread="9.583"/>
                    <measurement group_id="O8" value="-4.29" spread="13.497"/>
                    <measurement group_id="O9" value="-11.25" spread="23.692"/>
                    <measurement group_id="O10" value="-1.41" spread="8.810"/>
                    <measurement group_id="O11" value="0.32" spread="22.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20,n=124,116,120,127,38,37,23,21,91,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.19" spread="32.876"/>
                    <measurement group_id="O2" value="-8.05" spread="22.394"/>
                    <measurement group_id="O3" value="-3.75" spread="29.301"/>
                    <measurement group_id="O4" value="-9.43" spread="23.212"/>
                    <measurement group_id="O5" value="-5.33" spread="20.645"/>
                    <measurement group_id="O6" value="-7.77" spread="27.581"/>
                    <measurement group_id="O7" value="3.23" spread="48.634"/>
                    <measurement group_id="O8" value="-1.06" spread="15.737"/>
                    <measurement group_id="O9" value="-11.59" spread="24.271"/>
                    <measurement group_id="O10" value="-3.94" spread="15.716"/>
                    <measurement group_id="O11" value="-3.99" spread="32.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk24,n=121,113,116,120,37,36,21,22,86,16,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.90" spread="22.098"/>
                    <measurement group_id="O2" value="-4.92" spread="23.075"/>
                    <measurement group_id="O3" value="-6.88" spread="21.014"/>
                    <measurement group_id="O4" value="-8.66" spread="21.574"/>
                    <measurement group_id="O5" value="-7.06" spread="20.298"/>
                    <measurement group_id="O6" value="-11.46" spread="26.373"/>
                    <measurement group_id="O7" value="-6.40" spread="11.562"/>
                    <measurement group_id="O8" value="0.45" spread="18.244"/>
                    <measurement group_id="O9" value="-11.72" spread="22.198"/>
                    <measurement group_id="O10" value="-4.94" spread="13.605"/>
                    <measurement group_id="O11" value="2.63" spread="20.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk28,n=119,110,na,na,34,35,21,21,89,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.94" spread="23.155"/>
                    <measurement group_id="O2" value="-5.87" spread="25.885"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-4.43" spread="21.777"/>
                    <measurement group_id="O6" value="-11.10" spread="27.186"/>
                    <measurement group_id="O7" value="-7.97" spread="18.018"/>
                    <measurement group_id="O8" value="0.09" spread="24.933"/>
                    <measurement group_id="O9" value="-12.08" spread="22.791"/>
                    <measurement group_id="O10" value="-4.51" spread="14.144"/>
                    <measurement group_id="O11" value="-1.70" spread="22.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32,n=107,101,na,na,34,32,20,21,87,17,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.57" spread="20.826"/>
                    <measurement group_id="O2" value="7.37" spread="24.564"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-4.34" spread="23.742"/>
                    <measurement group_id="O6" value="-9.08" spread="25.867"/>
                    <measurement group_id="O7" value="-5.02" spread="10.300"/>
                    <measurement group_id="O8" value="-5.51" spread="14.279"/>
                    <measurement group_id="O9" value="-12.83" spread="23.330"/>
                    <measurement group_id="O10" value="-4.26" spread="15.329"/>
                    <measurement group_id="O11" value="-7.14" spread="17.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk36,n=107,98,na,na,32,31,21,20,85,18,15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.60" spread="25.895"/>
                    <measurement group_id="O2" value="-6.36" spread="22.571"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-4.21" spread="27.424"/>
                    <measurement group_id="O6" value="-2.35" spread="37.226"/>
                    <measurement group_id="O7" value="-2.73" spread="21.272"/>
                    <measurement group_id="O8" value="-6.78" spread="13.940"/>
                    <measurement group_id="O9" value="-12.19" spread="24.535"/>
                    <measurement group_id="O10" value="-4.38" spread="14.479"/>
                    <measurement group_id="O11" value="-0.47" spread="27.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WK40,n=101,96,na,na,29,29,22,20,86,15,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.74" spread="22.257"/>
                    <measurement group_id="O2" value="-7.09" spread="24.325"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-7.07" spread="26.156"/>
                    <measurement group_id="O6" value="2.39" spread="32.966"/>
                    <measurement group_id="O7" value="-4.46" spread="22.808"/>
                    <measurement group_id="O8" value="-4.73" spread="13.502"/>
                    <measurement group_id="O9" value="-12.63" spread="23.788"/>
                    <measurement group_id="O10" value="-2.75" spread="17.297"/>
                    <measurement group_id="O11" value="-7.95" spread="18.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk44,n=97,92,na,na,,28,28,20,19,85,15,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.59" spread="20.975"/>
                    <measurement group_id="O2" value="-7.25" spread="24.681"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-6.66" spread="23.396"/>
                    <measurement group_id="O6" value="-8.53" spread="19.970"/>
                    <measurement group_id="O7" value="-6.50" spread="19.968"/>
                    <measurement group_id="O8" value="-7.27" spread="13.887"/>
                    <measurement group_id="O9" value="-12.32" spread="25.470"/>
                    <measurement group_id="O10" value="-1.33" spread="4.846"/>
                    <measurement group_id="O11" value="-3.69" spread="24.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk48,n=97,91,na,na,28,29,20,19,79,13,14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.19" spread="18.912"/>
                    <measurement group_id="O2" value="-7.63" spread="21.682"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-10.49" spread="25.564"/>
                    <measurement group_id="O6" value="-4.76" spread="15.784"/>
                    <measurement group_id="O7" value="-1.43" spread="33.122"/>
                    <measurement group_id="O8" value="-6.97" spread="13.680"/>
                    <measurement group_id="O9" value="-13.90" spread="25.636"/>
                    <measurement group_id="O10" value="-3.50" spread="21.343"/>
                    <measurement group_id="O11" value="-4.48" spread="16.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk52,n=95,92,na,na,29,28,20,18,83,16,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.68" spread="26.240"/>
                    <measurement group_id="O2" value="-8.14" spread="22.149"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-4.63" spread="25.795"/>
                    <measurement group_id="O6" value="-4.79" spread="22.882"/>
                    <measurement group_id="O7" value="2.95" spread="9.880"/>
                    <measurement group_id="O8" value="-4.88" spread="11.707"/>
                    <measurement group_id="O9" value="-11.19" spread="27.768"/>
                    <measurement group_id="O10" value="-6.73" spread="14.972"/>
                    <measurement group_id="O11" value="-5.78" spread="18.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data</title>
        <description>Blood samples were obtained to monitor disease activity and response to treatment. A negative change from baseline indicates improvement. The ESR results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
        <time_frame>baseline, weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52</time_frame>
        <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 10mg/kg - 75 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>AIN457 10mg/kg - 150 mg</title>
            <description>Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
          </group>
          <group group_id="O4">
            <title>Abatacept</title>
            <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
          </group>
          <group group_id="O5">
            <title>Placebo Non-responder - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 16.</description>
          </group>
          <group group_id="O6">
            <title>Placebo Non-responder - AIN457 150mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 16.</description>
          </group>
          <group group_id="O7">
            <title>Placebo Responder - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O8">
            <title>Placebo Responder - AIN457 150mg</title>
            <description>Participants switched from placebo to AIN457 150 mg starting at week 24.</description>
          </group>
          <group group_id="O9">
            <title>Abatacept Responders</title>
            <description>Abatacept responders remained on abatacept (from 500 to 1000 mg iv based on weight).</description>
          </group>
          <group group_id="O10">
            <title>Abatacept Non-responders - AIN457 75mg</title>
            <description>Participants switched from placebo to AIN457 75 mg starting at week 24.</description>
          </group>
          <group group_id="O11">
            <title>Abatacept Non-responders - AIN457 150mg</title>
            <description>Participants switched from abatacept to AIN457 150 mg starting at week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocyte Sedimentation Rate (ESR) - Observed Data</title>
          <description>Blood samples were obtained to monitor disease activity and response to treatment. A negative change from baseline indicates improvement. The ESR results from baseline up to week 52 were based on observed data, i.e. without imputation.</description>
          <population>Participants from the full analysis set were considered for the analysis. Participants with measurements at both baseline and each post-baseline time point were analyzed for that post-baseline time point. The full analysis set was comprised of all randomized participants (excluding mis-randomized participants) who were assigned to study treatment.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="138"/>
                <count group_id="O4" value="138"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="22"/>
                <count group_id="O9" value="101"/>
                <count group_id="O10" value="18"/>
                <count group_id="O11" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk1,n=133,130,131,131,39,36,21,22,97,17,17,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="18.74"/>
                    <measurement group_id="O2" value="-8.4" spread="19.20"/>
                    <measurement group_id="O3" value="-5.7" spread="15.68"/>
                    <measurement group_id="O4" value="-9.5" spread="16.55"/>
                    <measurement group_id="O5" value="-8.4" spread="12.65"/>
                    <measurement group_id="O6" value="-1.1" spread="18.88"/>
                    <measurement group_id="O7" value="-5.7" spread="14.97"/>
                    <measurement group_id="O8" value="-7.1" spread="13.22"/>
                    <measurement group_id="O9" value="-10.2" spread="17.11"/>
                    <measurement group_id="O10" value="-7.7" spread="13.90"/>
                    <measurement group_id="O11" value="-7.2" spread="16.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk2,n=133,130,135,134,39,36,23,22,99,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.2" spread="19.06"/>
                    <measurement group_id="O2" value="-10.5" spread="19.05"/>
                    <measurement group_id="O3" value="-5.7" spread="18.22"/>
                    <measurement group_id="O4" value="-11.0" spread="19.50"/>
                    <measurement group_id="O5" value="-4.0" spread="12.69"/>
                    <measurement group_id="O6" value="-5.6" spread="26.44"/>
                    <measurement group_id="O7" value="-9.7" spread="17.86"/>
                    <measurement group_id="O8" value="-6.6" spread="14.44"/>
                    <measurement group_id="O9" value="-10.2" spread="20.33"/>
                    <measurement group_id="O10" value="-12.5" spread="16.71"/>
                    <measurement group_id="O11" value="-13.6" spread="17.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk4,n=133,135,131,133,39,39,23,21,97,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" spread="22.23"/>
                    <measurement group_id="O2" value="-12.1" spread="21.88"/>
                    <measurement group_id="O3" value="-6.0" spread="18.90"/>
                    <measurement group_id="O4" value="-12.6" spread="18.14"/>
                    <measurement group_id="O5" value="-3.7" spread="14.35"/>
                    <measurement group_id="O6" value="-3.8" spread="20.50"/>
                    <measurement group_id="O7" value="-9.3" spread="13.81"/>
                    <measurement group_id="O8" value="-8.2" spread="23.89"/>
                    <measurement group_id="O9" value="-12.3" spread="18.66"/>
                    <measurement group_id="O10" value="-15.8" spread="17.49"/>
                    <measurement group_id="O11" value="-11.3" spread="16.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk8,n=133,129,131,132,39,39,23,22,96,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" spread="20.38"/>
                    <measurement group_id="O2" value="-15.7" spread="21.62"/>
                    <measurement group_id="O3" value="-6.4" spread="22.72"/>
                    <measurement group_id="O4" value="-17.6" spread="20.89"/>
                    <measurement group_id="O5" value="-9.4" spread="19.24"/>
                    <measurement group_id="O6" value="-0.9" spread="27.25"/>
                    <measurement group_id="O7" value="-8.2" spread="24.09"/>
                    <measurement group_id="O8" value="-8.3" spread="14.29"/>
                    <measurement group_id="O9" value="-18.3" spread="21.56"/>
                    <measurement group_id="O10" value="-13.9" spread="23.29"/>
                    <measurement group_id="O11" value="-17.6" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk12,n=133,118,127,131,39,39,23,21,96,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" spread="20.08"/>
                    <measurement group_id="O2" value="-18.4" spread="21.18"/>
                    <measurement group_id="O3" value="-5.8" spread="21.02"/>
                    <measurement group_id="O4" value="-19.4" spread="20.97"/>
                    <measurement group_id="O5" value="-5.9" spread="17.96"/>
                    <measurement group_id="O6" value="-1.5" spread="25.62"/>
                    <measurement group_id="O7" value="-11.2" spread="18.06"/>
                    <measurement group_id="O8" value="-5.5" spread="20.06"/>
                    <measurement group_id="O9" value="-19.9" spread="21.08"/>
                    <measurement group_id="O10" value="-18.4" spread="23.07"/>
                    <measurement group_id="O11" value="-17.9" spread="19.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk16,n=129,121,122,130,36,38,21,22,95,16,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.2" spread="21.22"/>
                    <measurement group_id="O2" value="-15.6" spread="19.09"/>
                    <measurement group_id="O3" value="-6.5" spread="23.48"/>
                    <measurement group_id="O4" value="-18.5" spread="24.32"/>
                    <measurement group_id="O5" value="-3.1" spread="19.21"/>
                    <measurement group_id="O6" value="-1.1" spread="25.47"/>
                    <measurement group_id="O7" value="-17.6" spread="23.03"/>
                    <measurement group_id="O8" value="-4.9" spread="20.54"/>
                    <measurement group_id="O9" value="-21.1" spread="24.73"/>
                    <measurement group_id="O10" value="-14.9" spread="17.78"/>
                    <measurement group_id="O11" value="-8.8" spread="25.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk20,n=123,116,120,127,38,37,23,21,91,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" spread="20.90"/>
                    <measurement group_id="O2" value="-17.7" spread="19.90"/>
                    <measurement group_id="O3" value="-9.1" spread="26.29"/>
                    <measurement group_id="O4" value="-21.1" spread="23.66"/>
                    <measurement group_id="O5" value="-21.1" spread="23.66"/>
                    <measurement group_id="O6" value="-10.5" spread="20.08"/>
                    <measurement group_id="O7" value="-7.4" spread="29.40"/>
                    <measurement group_id="O8" value="-11.6" spread="34.23"/>
                    <measurement group_id="O9" value="-7.0" spread="22.32"/>
                    <measurement group_id="O10" value="-22.0" spread="23.60"/>
                    <measurement group_id="O11" value="-20.5" spread="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk24,n=122,113,117,123,38,36,21,22,88,17,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.9" spread="23.65"/>
                    <measurement group_id="O2" value="-16.0" spread="20.20"/>
                    <measurement group_id="O3" value="-12.0" spread="24.31"/>
                    <measurement group_id="O4" value="-19.6" spread="24.52"/>
                    <measurement group_id="O5" value="-10.8" spread="20.33"/>
                    <measurement group_id="O6" value="-14.7" spread="27.77"/>
                    <measurement group_id="O7" value="-16.1" spread="21.57"/>
                    <measurement group_id="O8" value="-5.5" spread="27.07"/>
                    <measurement group_id="O9" value="-21.1" spread="24.62"/>
                    <measurement group_id="O10" value="-20.7" spread="20.65"/>
                    <measurement group_id="O11" value="-11.4" spread="26.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk28,n=119,110,na,na,34,35,21,21,89,17,19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" spread="22.95"/>
                    <measurement group_id="O2" value="-16.8" spread="23.05"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-17.9" spread="24.87"/>
                    <measurement group_id="O6" value="-12.5" spread="30.87"/>
                    <measurement group_id="O7" value="-12.3" spread="24.10"/>
                    <measurement group_id="O8" value="-14.6" spread="17.31"/>
                    <measurement group_id="O9" value="-22.4" spread="22.90"/>
                    <measurement group_id="O10" value="-26.1" spread="19.83"/>
                    <measurement group_id="O11" value="-17.4" spread="24.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk32,n=108,101,na,na,34,32,21,21,88,17,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="23.51"/>
                    <measurement group_id="O2" value="-17.4" spread="21.57"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-17.2" spread="16.70"/>
                    <measurement group_id="O6" value="-12.8" spread="26.21"/>
                    <measurement group_id="O7" value="-16.8" spread="24.37"/>
                    <measurement group_id="O8" value="-14.1" spread="20.72"/>
                    <measurement group_id="O9" value="-25.5" spread="24.89"/>
                    <measurement group_id="O10" value="-25.7" spread="21.14"/>
                    <measurement group_id="O11" value="-23.1" spread="21.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk36,n=107,98,na,na,32,31,21,20,87,18,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" spread="25.20"/>
                    <measurement group_id="O2" value="-18.4" spread="21.51"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-17.8" spread="21.72"/>
                    <measurement group_id="O6" value="-13.4" spread="29.49"/>
                    <measurement group_id="O7" value="-17.3" spread="22.02"/>
                    <measurement group_id="O8" value="-16.5" spread="17.95"/>
                    <measurement group_id="O9" value="-21.7" spread="25.40"/>
                    <measurement group_id="O10" value="-26.0" spread="21.21"/>
                    <measurement group_id="O11" value="-16.6" spread="23.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk40,n=101,96,na,na,29,29,22,20,85,15,17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.1" spread="21.06"/>
                    <measurement group_id="O2" value="-17.3" spread="21.05"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-20.6" spread="19.66"/>
                    <measurement group_id="O6" value="-12.3" spread="26.37"/>
                    <measurement group_id="O7" value="-13.3" spread="18.78"/>
                    <measurement group_id="O8" value="-16.4" spread="21.79"/>
                    <measurement group_id="O9" value="-22.2" spread="26.24"/>
                    <measurement group_id="O10" value="-23.8" spread="22.96"/>
                    <measurement group_id="O11" value="-22.9" spread="15.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk44,n=98,93,na,na,28,28,20,19,85,15,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.0" spread="21.08"/>
                    <measurement group_id="O2" value="-16.7" spread="23.87"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-20.1" spread="17.61"/>
                    <measurement group_id="O6" value="-16.0" spread="25.30"/>
                    <measurement group_id="O7" value="-12.0" spread="29.20"/>
                    <measurement group_id="O8" value="-19.2" spread="22.57"/>
                    <measurement group_id="O9" value="-24.9" spread="25.66"/>
                    <measurement group_id="O10" value="-22.3" spread="23.36"/>
                    <measurement group_id="O11" value="-18.5" spread="21.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk48,n=97,92,na,na,28,30,20,19,79,13,14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.8" spread="23.11"/>
                    <measurement group_id="O2" value="-19.8" spread="20.30"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-20.8" spread="18.26"/>
                    <measurement group_id="O6" value="-7.2" spread="22.58"/>
                    <measurement group_id="O7" value="-12.2" spread="29.55"/>
                    <measurement group_id="O8" value="-19.4" spread="20.58"/>
                    <measurement group_id="O9" value="-23.9" spread="25.56"/>
                    <measurement group_id="O10" value="-18.9" spread="26.41"/>
                    <measurement group_id="O11" value="-20.2" spread="18.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk52,n=94,91,na,na,29,28,20,18,83,16,16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" spread="21.08"/>
                    <measurement group_id="O2" value="-20.6" spread="23.48"/>
                    <measurement group_id="O3" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O4" value="NA">After week 24, placebo and abatacept analysis was done on 'AIN457 switch' groups only.</measurement>
                    <measurement group_id="O5" value="-14.9" spread="20.53"/>
                    <measurement group_id="O6" value="-15.1" spread="21.50"/>
                    <measurement group_id="O7" value="-14.4" spread="24.54"/>
                    <measurement group_id="O8" value="-13.6" spread="27.16"/>
                    <measurement group_id="O9" value="-25.2" spread="27.88"/>
                    <measurement group_id="O10" value="-27.4" spread="22.71"/>
                    <measurement group_id="O11" value="-15.4" spread="22.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Any AIN457 75 mg</title>
          <description>Any AIN457 75 mg</description>
        </group>
        <group group_id="E2">
          <title>Any AIN457 150 mg</title>
          <description>Any AIN457 150 mg</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (&gt;= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.</description>
        </group>
        <group group_id="E4">
          <title>Abatacept</title>
          <description>Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Eye abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired claw toe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Formication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Meningorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Perineurial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Lipoprotein (a) increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

